We need your donations to support our seed  money grant  program for new research as well as our educational and support activities.
Every week, Dr. Barken and other leading world experts answer your questions LIVE in a telephone call-in show. You can call in and ask your questions, or just listen in!
1-877-PCREF-01(Toll-Free)
When: Tuesday, 6-7 pm PST and Saturday 12 Noon PST


Click here only at the time of Tuesday's live audio stream show at 6pm-7pm PST

Click here only at the time of Saturday's live audio stream show at 12:00-13:00 PST

Leave a question anytime during the week at 1-877-727-3301 (toll-free). The Telephone Question Bank is open 24/7!

Past Call-In Shows
To download previous shows on your Ipod, please
click here:
Future Call-In Shows
Review Articles
Ask Dr. Barken Call-In Show
Live Internet Webcast
Get Your Own Medical History Graph
Join Noscapine email list
Join the C2P email list
The MEDS Principles
Dr. Barken's Decision Making Pyramid
"PC-REF Reporter" Newsletter
Pixels For Prostate Cancer

Welcome to PC-REF’s website. Here you will find not only useful information, but guidance on how to utilize this information. With PC-REF, you will become an active partner in your treatment decisions, not merely an informed patient.
Dr. Israel "The Coach" Barken
 

To provide seed money for innovative prostate cancer research, to seek out new diagnostic and therapeutic tools, to provide support to prostate cancer patients and loved ones, and to provide education to the general public with the goal of increasing awareness of prostate cancer, its management and the need for patient involvement in treatment decisions.

Click here to learn more

  
Dr. Israel Barken made a presentation at the 17th International Prostate Cancer Update conference in Vail, Colorado on Feb. 15th, 2007. He presented the result of research demonstrating the effect of Noscapine on prostate cancer cells implanted in mice. The results showed significant inhibition of the growth of the primary tumor and significantly less metastatic disease in the treated animal group.
Please click here for the press release.
For information about Noscapine please click here.
   
Samarium and Taxotere
A Phase I/II Trial of Samarium (Sm-153) Lexidronam Combined with Docetaxel for Patients with Androgen-Independent Prostate Cancer [Protocol 05-014] View More..
 
Cryoablation and Penile Rehabilitation
Cryoablation as Primary Treatment for Localized Prostate Cancer Followed by Penile Rehabilitation View More..
 
Focal Cryosurgery
Focal Cryosurgery: Encouraging Health Outcomes for Unifocal Prostate Cancer Erica H. Lambert, Kimberly Bolte, Puneet Masson, and Aaron E. Katz View More..
 
10 years follow up - Cryosurgery
Ten-Year Biochemical Disease Cotrol for patients with Prostate Cancer treated with Cryosurgery as Primary Treament View More..
 
P53 as predictor of outcome for radiation
p53 Protein Expression Status and Recurrence in Men Treated with Radiation and Androgen Suppression Therapy for Higher-Risk Prostate Cancer: A Prospective Phase II Cancer and Leukemia Group B Study (CALGB 9682) View More..
 
Click here for more

Medical Smart Chart
Click here to login
ISRAEL BARKEN, M.D., F.A.C.S. and Medical Director

Dr. Barken devotes his time to patient support activities, such as Coaching and providing Medical Reviews for prostate cancer patients and their loved ones. He is able to focus on finding and evaluating new research opportunities to be funded by PC-REF that can open the door to better treatments and better technology for today’s prostate cancer patients.

Click here to learn more
 
ACTIVITIES
Local Activities-San Diego Area
Internet Programs - Worldwide
 
Webcast Live on the Internet Featured Speaker Series :
11:00 AM - 12:30 PM Pacific Time
2:00PM Eastern time, 6:00PM GMT DATE: Second Saturday, June 14,2008
Speaker : Mauricio Zanetti, M.D., Professor and nationally known researcher, UCSD
Topic : Developing a Vaccine for Prostate Cancer
 
Home Feedback  |  Site Map  |  Contact Us  |  Disclaimer | Privacy Policy
Copyright © 2005 Prostate Cancer Research and Education Foundation. All Rights Reserved.